Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study.
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
Kraut
E H
EH
Ohio State University Health Center, Columbus.
Fleming
T
T
Segal
M
M
Neidhart
J A
JA
Behrens
B C
BC
MacDonald
J
J
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D006690:Bisbenzimidazole / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D006690:Bisbenzimidazole